Wilmington Savings Fund Society FSB Acquires Shares of 8,000 Dynavax Technologies Co. (NASDAQ:DVAX)

Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $89,000.

A number of other large investors have also made changes to their positions in DVAX. Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at $17,615,000. Great Point Partners LLC boosted its position in shares of Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Dynavax Technologies in the third quarter valued at about $8,291,000. PDT Partners LLC acquired a new stake in Dynavax Technologies during the third quarter worth about $3,967,000. Finally, Mizuho Markets Americas LLC raised its stake in Dynavax Technologies by 37.9% during the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after purchasing an additional 323,050 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.72 on Friday. The firm has a 50-day simple moving average of $12.24 and a two-hundred day simple moving average of $11.52. The stock has a market cap of $1.67 billion, a PE ratio of 97.85 and a beta of 1.33. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.